Ajanta Pharma Ltd. News and Updates

Name: Latest research reports of Ajanta Pharma Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Ajanta Pharma Ltd.
Rating: 3
Author: ICICI Securities Limited

Keep track of all breaking news on Ajanta Pharma Ltd. from all sources in a single place.

Load latest

Ajanta Pharma Ltd.

05 Nov 2019

2485.25

-5.18%

Ajanta Pharma Q2 net profit dips 7% to Rs 116 crore; stock ends flat

Business Standard

Income from operations rose to Rs 643 crore during the period under review, as compared with Rs 544 crore in the year-ago period

Ajanta Pharma Ltd. has an average target of 2987.67 from 3 brokers.

Ajanta Pharma Ltd.

03 Sep 2019, 05:51PM

2485.25

-5.18%

Domestic business driving Ajanta Pharma's growth prospects

Business Standard

Industry beating growth along with high US sales are keeping analysts positive on the company's earnings prospects

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

06 Aug 2019

2485.25

-5.18%

Ajanta Pharma Ltd. - Result Update - 06 August 2019

Results Update: Ajanta Pharma Ltd.

Way2Wealth

Ajanta reported growth across most of the financial line items YoY and QoQ. Revenue/EBITDA/PAT grew by 20%/7%/9%YoY, while sequentially it grew by 19%/32%/30%. However, gross and EBITDA margins declined 700bps and 335bps YoY....

Ajanta Pharma Ltd. has lost -25.83% in the last 6 Months

Ajanta Pharma Ltd.

02 Aug 2019

2485.25

-5.18%

Ajanta Pharma (957.3): Buy

Business Line

The stock of Ajanta Pharma was on highlight on Thursday and gained 8.6 per cent accompanied by extraordinary volume. This rally gives investors with a

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

01 Aug 2019

2485.25

-5.18%

Ajanta Pharma rises on Q1 profit

Business Line

Generic drugmaker Ajanta Pharma's shares have risen as much as 3.8 percent to 915, the biggest daily percentage gain since July 16.The company has p

Ajanta Pharma Ltd. has an average target of 2987.67 from 3 brokers.

Ajanta Pharma Ltd.

01 Aug 2019

2485.25

-5.18%

Ajanta Pharma - 1QFY20 Result Update

Ajanta Pharma Ltd.

Reliance Securities

Ajanta Pharma Ltd. has an average target of 2987.67 from 3 brokers.

Ajanta Pharma Ltd.

01 Aug 2019

2485.25

-5.18%

Ajanta Pharmaceuticals

Hold: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

Domestic formulations - Focus on new launches, few therapies Domestic formulations comprise 33% of FY19 revenues. The main distinguishing factor is the uncanny knack of launching maximum number of first time launches with focus on new drug delivery system (NDDS). Out of 270+ actively marketed brands, ~60% were first time launches. However, a slowdown in dermatology segment due to increased competition in existing products and slow offtake in new launches are some near term challenges. We expect domestic formulations to grow at ~12% CAGR in...

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

02 May 2019

2485.25

-5.18%

Ajanta Pharmaceuticals

Hold: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

Domestic formulations comprise 33% of FY19 revenues. The main distinguishing factor is the uncanny knack of launching maximum number of first time launches with focus on new drug delivery system (NDDS). Out of 270+ actively marketed brands, ~60% were first time launches. However, a slowdown in the dermatology segment due to increased competition in existing products and slow offtake in new launches may impact near term...

Ajanta Pharma Ltd.'s price crossed below 30Day SMA today

Ajanta Pharma Ltd.

01 May 2019

2485.25

-5.18%

Africa/institutional anti-malaria drag performance???

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

1 May 2019 Revenue declined 3% YoY to INR5.1b (in-line) in 4QFY19, largely on account of the weakness in (a) institutional anti-malaria (-26% YoY; 9% of sales) and (b) Africa branded generic (-31% YoY; 15% of sales) businesses. However, the impact was partly mitigated by the ramp-up in US sales (+79% YoY; 15% of sales) and steady growth in the India business (+8% YoY; 30% of sales)/Asia (+9% YoY; 28% of sales). EBITDA margin, too, contracted 164bp YoY to 24.7% (our v/s 19.8% in the year-ago period) and RM cost. Other expenses, however, declined to 34% of sales (36.2% in 4QFY18), providing some comfort to the FY19, sales/EBITDA/PAT declined 4%/14%/17% YoY to INR20.5b/INR5.6b/INR3.8b. In FY19, AJP filed 13 and received 12 ANDA approvals (including two tentative approvals). The company has commercialized 25 ANDAs till date.